000			02034 a2200565 4500
005			20250516110957.0
264		0	_c20130426
008			201304s 0 0 eng d
022			_a2040-2058
024	7		_a10.3851/IMP2350 _2doi
040			_aNLM _beng _cNLM
100	1		_aLichtenstein, Kenneth A
245	0	0	_aA pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. _h[electronic resource]
260			_bAntiviral therapy _c2012
300			_a1301-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntiretroviral Therapy, Highly Active _xmethods
650	0	4	_aBiomarkers _xmetabolism
650	0	4	_aCD4-CD8 Ratio
650	0	4	_aCD4-Positive T-Lymphocytes _ximmunology
650	0	4	_aCD8-Positive T-Lymphocytes _ximmunology
650	0	4	_aChemokine CCL5 _xmetabolism
650	0	4	_aDisease Progression
650	0	4	_aFemale
650	0	4	_aHIV Infections _xdrug therapy
650	0	4	_aHIV-1 _xpathogenicity
650	0	4	_aHumans
650	0	4	_aImmunologic Memory
650	0	4	_aInflammation _ximmunology
650	0	4	_aInflammation Mediators _ximmunology
650	0	4	_aLymphocyte Activation
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPilot Projects
650	0	4	_aPyrrolidinones _xpharmacology
650	0	4	_aRaltegravir Potassium
650	0	4	_aViral Load
650	0	4	_agag Gene Products, Human Immunodeficiency Virus _ximmunology
650	0	4	_anef Gene Products, Human Immunodeficiency Virus _ximmunology
700	1		_aArmon, Carl
700	1		_aNagabhushanam, Vijaya
700	1		_aEfaw, Benjamin J
700	1		_aFrazer-Abel, Ashley
700	1		_aHiserote, Melissa E
700	1		_aAlam, Rafeul
773	0		_tAntiviral therapy _gvol. 17 _gno. 7 _gp. 1301-9
856	4	0	_uhttps://doi.org/10.3851/IMP2350 _zAvailable from publisher's website
999			_c22076722 _d22076722